Consensus $9.70. Raises FY25 revenue view to $10.8B-$10.92B from $10.7B-$10.85B, consensus $10.79B. Backs FY25 capital expenditures view $500M. The company said, “Demand for our innovative clinical solutions and expanded business from enterprise accounts complemented growth from acquisitions. We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Notable companies reporting before tomorrow’s open
- Quest Diagnostics price target lowered to $175 from $176 at UBS
- Quest Diagnostics introduces testing for Oropouche virus
- Quest Diagnostics: Strategic Positioning and Growth Potential Amid Reimbursement Challenges
- Quest Diagnostics to develop multi-cancer blood test with MD Anderson Center